Yili Chuanning Biotechnology Co., Ltd.
Research Yili Chuanning Biotechnology Co., Ltd. (301301.SZ) on Bullrun: market cap CNY 17.68B, P/E 36.0, dividend yield 2.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker301301.SZ
- ExchangeSZ
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyCNY
- Market capCNY 17.68B
- P/E36.0
- Dividend yield2.2%
- Financial periodQ2 2026
- RevenueCNY 1.00B
- Net incomeCNY 166.78M
- Free cash flowCNY 579.83M
- Gross margin29.3%
Valuation Snapshot
latest market cap is CNY 17.68B; P/E is 36.0; dividend yield is 2.2%.
Peer valuation comparison
Latest P/E is 36x versus a Healthcare sector median of 21.8x (65.2% above).
Latest dividend yield is 2.18% versus a Healthcare sector median of 2.4% (9.2% below).
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-11 | CNY 17.68B | 36.0 | 2.2% | 0.17 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.17 CNY, yield 2.2%.
About Yili Chuanning Biotechnology Co., Ltd.
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA;
ETFs that hold Yili Chuanning Biotechnology Co., Ltd.
US-listed ETFs
Yili Chuanning Biotechnology Co., Ltd. is held by 11 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| Vanguard Total International Stock Index Fund ETF Shares (VXUS) | <0.01% | 0.05% |
| Vanguard FTSE Emerging Markets Index Fund ETF Shares (VWO) | <0.01% | 0.06% |
| Vanguard Total World Stock Index Fund ETF Shares (VT) | <0.01% | 0.06% |
| Vanguard FTSE All-World ex-US Index Fund ETF Shares (VEU) | <0.01% | 0.04% |
| Schwab Emerging Markets Equity ETF (SCHE) | <0.01% | 0.06% |
| Vanguard ESG International Stock ETF (VSGX) | <0.01% | 0.10% |
| VanEck ChiNext Innovators ETF (CNXT) | 0.07% | 0.65% |
| Franklin FTSE China ETF (FLCH) | 0.01% | 0.19% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Yili Chuanning Biotechnology Co., Ltd.'s market cap?
Yili Chuanning Biotechnology Co., Ltd.'s market capitalization is CNY 17.68B.
What is Yili Chuanning Biotechnology Co., Ltd.'s P/E ratio?
Yili Chuanning Biotechnology Co., Ltd.'s price-to-earnings (P/E) ratio is 36.0.
Does Yili Chuanning Biotechnology Co., Ltd. pay a dividend?
Yili Chuanning Biotechnology Co., Ltd. has a dividend yield of 2.2%.
What does Yili Chuanning Biotechnology Co., Ltd. do?
Yili Chuanning Biotechnology Co.,Ltd., together with its subsidiaries, engages in the research, development, and industrialization of bio-fermentation technology and synthetic biology products in China and internationally. It offers antibiotic intermediates comprising erythromycin thiofluorate; cephalosporin intermediates consisting of 7-aminocephalosporanic acid (7-ACA), 7-amino-3-deacetoxycephalosporinic acid (7-ADCA), and D-7ACA; penicillin intermediates, such as 6-aminopenicillanic acid (6-APA) and penicillin G potassium salt; ursodeoxycholic acid; coenzyme Q10 mycelia; and other products.